Clinical interventions in diabetic renal disease

Area of Science:

• Nephrology
• Endocrinology
• Cardiovascular Medicine

Background:

• Diabetic nephropathy is the primary cause of end-stage renal disease in North America and Western Europe.
• Glomerular filtration rate naturally decreases with age, a process potentially exacerbated in diabetic patients.
• Hypertension significantly contributes to the progression of diabetic renal disease.

Purpose of the Study:

• To review the impact of blood pressure control and specific pharmacotherapies on diabetic renal disease progression.
• To evaluate the renoprotective effects of angiotensin-converting enzyme inhibitors in diabetic patients with varying blood pressure levels and albuminuria.
• To discuss the role of glycemic control in the incidence and progression of microalbuminuria and overt nephropathy.

Main Methods:

• Literature review and synthesis of existing clinical data.
• Analysis of studies investigating blood pressure management in diabetic nephropathy.
• Evaluation of clinical trials on angiotensin-converting enzyme inhibitors in hypertensive and normotensive diabetic patients with albuminuria.

Main Results:

• Adequate blood pressure control limits glomerular filtration rate decline in hypertensive diabetic nephropathy.
• Angiotensin-converting enzyme inhibitors provide specific renoprotection beyond blood pressure reduction in hypertensive diabetic patients.
• Normotensive patients with microalbuminuria may also benefit from angiotensin-converting enzyme inhibitors, possibly due to masked hypertension.

Conclusions:

• Optimal blood pressure management is crucial for preserving kidney function in diabetic renal disease.
• Angiotensin-converting enzyme inhibitors are valuable therapeutic agents for renoprotection in diabetic patients.
• Further research is needed to clarify the role of glycemic control in preventing the progression of diabetic nephropathy.